Evidence map›Paper›PMID 33292365›Full record

ArticleInfectious agents and cancer2020

The clinical and translational research activities at the INT - IRCCS "Fondazione Pascale" cancer center (Naples, Italy) during the COVID-19 pandemic.

Franco M Buonaguro, Gerardo Botti, Paolo Antonio Ascierto, Sandro Pignata, Franco Ionna, Paolo Delrio, Antonella Petrillo, Ernesta Cavalcanti, Maurizio Di Bonito, Sisto Perdonà and 20 more

Open access · goldAbstract read
In one paragraph

Article in Infectious agents and cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 1 institution in 1 country.

Franco M BuonaguroIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy. fm.buonaguro@istitutotumori.na.it.ORCID http://orcid.org/0000-0002-7491-7220
Gerardo BottiIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Paolo Antonio AsciertoIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Sandro PignataIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Franco IonnaIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Paolo DelrioIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Antonella PetrilloIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Ernesta CavalcantiIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Maurizio Di BonitoIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Sisto PerdonàIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Michelino De LaurentiisIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Francesco FioreIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Raffaele PalaiaIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Francesco IzzoIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Stefania D'AuriaIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Virginia RossiIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Simona MenegozzoIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Mauro PiccirilloIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Egidio CelentanoIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Arturo CuomoIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Nicola NormannoIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Maria Lina TorneselloIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Rocco SavianoIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Daniela BarberioIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Luigi BuonaguroIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Giovanni GiannoniIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Paolo MutoIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Leonardo MiscioIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Attilio A M BianchiIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy. a.bianchi@istitutotumori.na.it.
and the INT-Pascale COVID-19 Crisis Unit
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · IT

Funding

Ministero della Salute WFR 2611892Regione Campania DRG N.140/2020
6 · The paper itself

Abstract

COVID-19 pandemic following the outbreak in China and Western Europe, where it finally lost the momentum, is now devastating North and South America. It has not been identified the reason and the molecular mechanisms of the two different patterns of the pulmonary host responses to the virus from a minimal disease in young subjects to a severe distress syndrome (ARDS) in older subjects, particularly those with previous chronic diseases (including diabetes) and cancer. The Management of the Istituto Nazionale Tumori - IRCCS "Fondazione Pascale" in Naples (INT-Pascale), along with all Health professionals decided not to interrupt the treatment of those hospitalized and to continue, even if after a careful triage in order not to allow SARS-CoV-2 positive subjects to access, to take care of cancer patients with serious conditions. Although very few (n = 3) patients developed a symptomatic COVID-19 and required the transfer to a COVID-19 area of the Institute, no patients died during the hospitalization and completed their oncology treatment. Besides monitoring of the patients, all employees of the Institute (physicians, nurses, researchers, lawyers, accountants, gatekeepers, guardians, janitors) have been tested for a possible exposure. Personnel identified as positive, has been promptly subjected to home quarantine and subdued to health surveillance. One severe case of respiratory distress has been reported in a positive employees and one death of a family member. Further steps to home monitoring of COVID-19 clinical course have been taken with the development of remote Wi-Fi connected digital devices for the detection of early signs of respiratory distress, including heart rate and oxygen saturation.In conclusion cancer care has been performed and continued safely also during COVID-19 pandemic and further remote home strategies are in progress to ensure the appropriate monitoring of cancer patients.

Indexed as

ARDSCancer centerCOVID-19IL-6ItalyPascaleSARS-CoV-2Tocilizumab

Identifiers

PMID33292365
PMCPMC7681193
OpenAlexW3108973885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.